Science in 2025: the best of the rest
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

Bayosthiti AI to build India-specific RNA sequencing ecosystem
Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc.

Science in 2025: the best of the rest
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Bayosthiti AI to build India-specific RNA sequencing ecosystem
Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc.
Holiday notice
In accordance with the publishing schedule, BioWorld Science will not be published on Thursday, Jan. 1, 2026, and Friday, Jan. 2, 2026.
Three Helius solid tumor candidates gain clinical trial clearance
Shanghai Henlius Biotech Inc. has announced acceptance of IND applications by China’s National Medical Products Administration (NMPA) for three differentiated candidates for the treatment of solid tumors.
BioWorld Science 2025 Year in Review
BioWorld Science looks back at the year’s biggest stories in research. Find all of our 2025 Year in Review articles here.
Hainan Simcere Pharmaceutical divulges new antibody-drug conjugates
Hainan Simcere Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising a glycoengineered antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.

BioWorld Insider podcast

The opioid crisis may not be front and center anymore, but it’s raging still. Elysium Therapeutics Inc. CEO Greg Sturmer talks about his firm’s candidate for a solution to the medical and societal problem.

Listen now

Conferences

Oncotartis’ OT-82 enhances venetoclax efficacy in AML
American Society of Hematology
Venetoclax has shown good results for adult acute myeloid leukemia (AML) in combination with azacitidine, but there is increasing evidence of inherent and acquired resistance. High expression of nicotinamide phosphoribosyltransferase (NAMPT) has been associated with cancer aggressiveness and poor...
ADCs’ breakout 2025 and their still-unfinished potential
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was reported, with innovations spanning targets, linkers, payloads, conjugation chemistries and overall architectures. Once defined by a simple “one...
Development and characterization of anti-CD19 in vivo CAR T therapy
CAR T
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR T candidate, named GT-801.
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
American Society of Hematology
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers from the Nara Medical University and collaborating institutions presented a potential therapeutic approach for AVWS.

Cancer

Histone reader ATAD2 as a therapeutic target in melanoma
Previous work showed that histone ‘readers’, which bind to post-translational modifications on histones, may be upregulated in melanoma and thereby upregulate oncogenes. Given that the histone reader ATAD2 is known to be overexpressed in several types of cancer, researchers at the University of...

Infection

Vaccine policy and the terrible, horrible, no good, very bad year
Immune
Driven by a deeply antiscientific political agenda, the current U.S. government is not just sabotaging some of the most groundbreaking technology that has been developed in the past decades. It is also destroying the country’s past successes, such as measles elimination and the reduction of...

Vaccines: From the toast of the town to being in the crosshairs
RNA
BioWorld’s 2022 end-of-year highlights included a toast to the future – of universal vaccines. Even before SARS-CoV-2 vaccines were developed in record time and saved countless lives during the COVID-19 pandemic, vaccines were a rare bright spot in the fight against infectious diseases. Bacteria...
CSPC’s SYH-2085 cleared for clinic in China to treat influenza
Regulatory
CSPC Pharmaceutical Group Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SYH-2085 tablets for the treatment of uncomplicated influenza A and B in adults and adolescents age 12 years and older.

Neurology/psychiatric

Apoptotic body-like liposomes restore immune tolerance in MS
Immune
Multiple sclerosis (MS) is a chronic immune-mediated disease characterized by the destruction of myelin sheaths, neuroaxonal damage, glial cell activation and formation of demyelinated plaques in the CNS. Since MS is considered a prototypic antigen-specific autoimmune disease, restoring immune...
2025 marks a breakthrough year for in vivo gene therapies
Drug design, drug delivery and technologies
Gene editing technologies are moving forward in preclinical development with innovative strategies designed to treat diseases at their root and even reverse them. However, many approaches still struggle to reach target cells or tissues – either they fail to arrive, or their efficacy is low. In vivo...
New NLRP3 inhibitors disclosed in Neushen Therapeutics patent
Patents
Neushen Therapeutics Inc. has divulged NLRP3 inhibitors reported to be useful for the treatment of neurodegeneration.
Syremis Therapeutics launches with focus on mental health
Financings
Syremis Therapeutics Ltd. has launched with $165 million in series A funding to develop novel medicines for the treatment of mental health disorders.
Researchers discover how glioblastoma tumors dodge chemotherapy
Drug design, drug delivery and technologies
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers new clues for future therapies. Glioblastoma is one of the deadliest brain cancers, accounting for about half of all brain tumors, with...

Endocrine/metabolic

CSPC cleared to advance SYH-2072 into clinic in China
Regulatory
CSPC Pharmaceutical Group Ltd. has obtained approval from the National Medical Products Administration (NMPA) in China to conduct clinical trials of SYH-2072 (tablets), a highly selective and potent aldosterone synthase inhibitor. It is being investigated as a potential treatment for uncontrolled...

Biomarkers

Mesothelin is biomarker, potential target in arthritic bone damage
Musculoskeletal
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences and Xi’an Jiao Tong University Health Science Center found that Mesothelin (MSLN) was significantly elevated in rheumatoid arthritis (RA)...

UK Biobank delivers largest metabolomics dataset of 500K profiles
Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its half a million participants.
‘Most complete’ map of oral microbiome enables links to systemic disease
Artificial intelligence
South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable...

Gastrointestinal

JAG1-boosting ASOs ameliorate liver pathology in Alagille syndrome
Genetic/congenital
Alagille syndrome (ALGS) is a rare, multisystem genetic disorder most commonly caused by haploinsufficiency of the JAG1 gene, leading to reduced JAG1 protein function and impaired development of intrahepatic bile ducts. Researchers from Arnatar...
Haisco Pharmaceutical discovers new TNF-α/TNFR1 interaction inhibitors
Patents
Haisco Pharmaceutical Group Co. Ltd. has described compounds acting as TNF-α/tumor necrosis factor receptor superfamily member 1A (TNFR1) interaction inhibitors reported to be useful for the treatment of psoriasis, Crohn’s disease, ulcerative...
Enveda’s ENV-6946 enters clinic for inflammatory bowel disease
Regulatory
Enveda has obtained IND clearance from the FDA and initiated a phase I trial of ENV-6946, a first-in-class oral small molecule for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Bispecific siRNA knocks down YAP1, WWTR1 with single guide strand
RNAi
Yes-associated protein (YAP), encoded by Yes1-associated transcriptional regulator (YAP1) and transcriptional coactivator with PDZ-binding motif (TAZ), encoded by WW domain containing transcription regulator 1 (WWTR1), are two crucial paralog...
Aerolysin-producing Aeromonas is behind ulcerative colitis
Infection
Researchers from the Medical School of Nanjing University hypothesized that in ulcerative colitis, the gut-resident macrophages may be compromised, leading to impaired integrity of the epithelial barrier. “From a basic science standpoint, our work...
Tangram seeks clinical trial clearance for TGM-312 for MASH
Regulatory
Tangram Therapeutics plc has submitted a clinical trial application (CTA) to the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II trial of TGM-312 for metabolic dysfunction-associated steatohepatitis (MASH).

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple background Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.

Recent episodes:

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, BioWorld Science and BioWorld Asia in a single, easy to access subscription

Today's news in brief

BioWorld

BioWorld MedTech

BioWorld Asia

BioWorld Science

BioWorld Premium